ANTIFUNGAL ACTIVITY AND GC-MS PROFILING OF A HYDROETHANOLIC EXTRACT OF CHELIDONIUM MAJUS L. AGAINST POTATO-ASSOCIATED FUSARIUM SPP

The article presents a preliminary GC-MS profile and antifungal activity of a hydroethanol extract of Chelidonium majus L. collected in the high-altitude conditions of the Kungei Alatau range (Kazakhstan). Antifungal activity was evaluated in vitro against one Fusarium spp. isolated from potato tubers with symptoms of fusarium lesion.

The extracts were obtained by Soxhlet extraction using 70% ethanol. The mycelial growth area was determined from digital images using ImageJ software. The experiment was carried out in four repetitions (n = 4). In the treatment with hydroethanolic extract of C. majus No. 1, the mycelial growth area of Fusarium spp. was 60.25 ± 4.08%, compared with 72.50 ± 2.65% in the solvent control containing 70% ethanol. Inhibition of mycelial growth relative to the solvent control was 16.9%. GC-MS analysis tentatively identified 11 compounds in the extract, among which ethyl esters of unsaturated fatty acids accounted for a substantial proportion (43.4%), followed by phytol (13.8%) and the compound 4H-Bis[1,3]benzodioxolo[5,6-a:4’,5’-g]quinolizine, 6,7,12b,13-tetrahydro-, (±) - (30.2%), tentatively identified based on mass-spectral library matching. The results obtained indicate the inhibitory activity of the hydroethanol extract of C. majus against the mycelial growth of Fusarium spp. in vitro and justify the need for further research.

1. Zare G., Diker N.Y., Arituluk Z.C., Tatli Cankaya I.I. (2021). Chelidonium majus L. (Papaveraceae) morphology, anatomy and traditional medicinal uses in Turkey. Istanbul Journal of Pharmacy, 51(1), 123 132. https://doi.org/10.26650/IstanbulJPharm.2020.0074.

2. Samatadze T.E., Yurkevich O.Y., Hazieva F.M., Konyaeva E.A., Morozov A.I., Zoshchuk S.A., Amosova A.V., Muravenko O.V. (2020). Agro-Morphological, Microanatomical and Molecular Cytogenetic Characterization of the Medicinal Plant Chelidonium majus L. Plants, 9, 1396. https ://doi.org/10.33 90/plants9101396.

3. Romanu R., Liga S., Tripon M.R., Huiban F., Iliescu D., Dehelean C.A., Camelia T. (2025). Chelidonium majus L.: A Current Perspective on Isoquinoline Alkaloids, Emerging Phytochemicals, Alkaloid Biosynthesis, and Biological Activities. Plants, 14, 2627. https://doi.org/10.3390/plants14172627.

4. Li X.L., Sun Y.P., Wang M., Wang Z.B., Kuang H.X. (2024). Alkaloids in Chelidonium majus L.: A review of its phytochemistry, pharmacology and toxicology. Frontiers in Pharmacology, 15, 1440979. https://doi.org/10.3389/tbhar.2024.1440979.

5. Borges A., Calvo M.L.M., Vaz J.A., Calhelha R.C. (2024). Enhancing wound healing: A comprehensive review of sericin and Chelidonium majus L. as potential dressings. Materials, 17, 4199. https://doi.org/10.3390/ma17174199.

6. Mukhtubayeva S.K., Dostemessova A.B., Izbastina K.S., Koblanova S.A., Zhumabekova B.K., Abdukadirova Zh.A. (2025). Assessment of the stocks of the main medicinal plant species in the eastern part of the Kungey Alatau Ridge. Bulletin of Al-Farabi Kazakh National University. Ecology Series, 3(84), 133-148. https://doi.org/10.26577/EJE202584313 [in Russian].

7. Nawrot R., Lippmann R., Matros A., Musidlak O., Nowicki G., Mock H.P. (2017). Proteomic comparison of Chelidonium majus L. latex in different phases of plant development. Plant Physiology and Biochemistry, 112, 312-325. https://doi.org/10.1016/i.plaphv.2017.01.010.

8. Nawrot J., Wilk-J^drusik M., Nawrot S., Nawrot K., Wilk B., Dawid-Pac R., Urbanska M., Micek I., Nowak G., Gornowicz-Porowska J. (2020). Milky Sap of Greater Celandine (Chelidonium majus L.) and Anti-Viral Properties. International Journal of Environmental Research and Public Health, 17(5), 1540. https://doi.org/10.3390/iierph17051540.

9. Chen P., Ji X.Y., Feng J.T., Wang X.Q., Zhang B. (2024). The Synergistic Mechanism of Chelidonium majus Alkaloids on Melanoma Treatment via a Multi-Strategy Insight. Molecules, 29, 5412. https://doi.org/10.3390/molecules29225412.

10. Gardin N.E., Braga A.J. (2021). Greater celandine (Chelidonium majus L.) for COVID-19: A twenty- case series. Phytotherapy Research, 35(7), 3792-3798. https://doi.org/10.1002/ptr.7085.

11. Stefanowski N., Tkachenko H., Osmolska U., Kurhaluk N. (2022). Dose-dependent alterations in the biomarkers of lipid and protein oxidation in the blood of patients with type 2 diabetes mellitus after in vitro incubation with extracts of Chelidonium majus L. Agrobiodiversity for Improving Nutrition, Health and Life Quality, 6(2). https://doi.org/10.15414/ainhlq.2022.0020.

12. Nawrot R., Warowicka A., Rudzki P.J., Musidlak O., Dolata K.M., Musijowski J., Stolarczyk E.U., Gozdzicka-Jozefiak A. (2021). Combined Protein and Alkaloid Research of Chelidonium majus Latex Reveals CmMLP1 Accompanied by Alkaloids with Cytotoxic Potential to Human Cervical Carcinoma Cells. International Journal of Molecular Sciences, 22(21), 11838. https://doi.org/10.3390/iims222111838.

13. Pantano F., Mannocchi G., Marinelli E., Gentili S., Graziano S., Busardo F.P., Di Luca N.M. (2017). Hepatotoxicity induced by greater celandine (Chelidonium majus L.): A review of the literature. European Review for Medical and Pharmacological Sciences, 21(1), 46-52.

14. Guo W., Lu X., Liu B., Yan H., Feng J. (2021). Anti-TMV activity and mode of action of three alkaloids isolated from Chelidonium majus. Pest Management Science, 77(1), 510-517. https://doi.org/10.1002/ps.6049.

15. Rahmonov O., Srodek D., Pytel S., Makieieva N., Kupka T. (2023). Relationships between Heavy Metal Concentrations in Greater Celandine (Chelidonium majus L.) Tissues and Soil in Urban Parks. International Journal of Environmental Research and Public Health, 20, 3887. https://doi.org/10.3390/iierph20053887.

16. Qi J., Zhang X., Guo X., Yang Y., Fan X., Han Y., Liu Y. (2024). Evaluation of the in vitro and in vivo antimicrobial activity of alkaloids prepared from Chelidonium majus L. using MRSA-infected C. elegans as a model host. Fitoterapia, 175, 105944. https://doi.org/10.1016/i.fitote.2024.105944.

17. Topor G., Stanescu C., Buzia O.D., Forna D.A., Serban C. (2024). Antimicrobial activity of Chelidonium majus L. Romanian Journal of Oral Rehabilitation, 16(3), 678. https://doi.org/10.6261/RJOR.2024.3.16.68. 18. Buzia O.D., Ion G.M., Earar K., Gurau G., Mardare N. (2022). Antimicrobial activity of Chelidonium majus L. Medical Materials, 2, 31-38. https://doi.org/10.36868/medmater.2022.02.01.031.

18. Izbastina K.S., Mukhtubayeva S.K., Dostemessova A., Kurmanbayeva M., Sitpayeva G., Ishmuratova M., Inelova Z., Sharipova (Zhumagul) M., Zhumadina S. (2026). Current State of Chelidonium majus L. (Papaveraceae) Populations in the Eastern Part of the Kungey Alatau Ridge (Southeastern Kazakhstan). Diversity, 18(3), 191. https://doi.org/10.3390/d18030191.

19. Sevindik M., et al. (2024). Biological activities of ethanol extracts of Hericium erinaceus obtained as a result of optimization analysis. Foods, 13(10), 1560. https://doi.org/10.3390/foods13101560.

20. Schneider C. A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis. Nature Methods. 2012. Vol. 9, No. 7. P. 671-675. https://doi.org/10.1038/nmeth.2089.

21. Onufrak A.J., Gazis R., Gwinn K., Klingeman W., Khodaei S., Perez Onate L.I., Finnell A., Givens S., Chen C., Holdridge D.R., Hadziabdic D. Potential biological control agents of Geosmithia morbida restrict fungal pathogen growth via mycoparasitism and antibiosis. BioControl. 2024. Vol. 69. P. 661-674. https://doi.org/10.1007/s10526-024-10277-y.

22. Dostemessova A.B., Ametov A.A., Kurmanbayeva M.S., Izbastina K.S. (2023). Biomorphological and phytochemical parameters of Chelidonium majus L. in the conditions of Kungei-Alatau. Fundamental and Experimental Biology, 28(3), 57-67. https://doi.org/10.31489/2023BMG3/57-67.

23. Colombo M.L., Bosisio E. (1996). Pharmacological activities of Chelidonium majus L. (Papaveraceae). Pharmacological Research, 33(2), 127-134. https://doi.org/10.1006/phrs.1996.0019.

24. Zielinska S., Jezierska-Domaradzka A., Wojciak-Kosior M., Sowa I., Junka A., Matkowski A.M. (2018). Greater Celandine's Ups and Downs - 21 Centuries of Medicinal Uses of Chelidonium majus from the Viewpoint of Today's Pharmacology. Frontiers in Pharmacology, 9, 299. https://doi.org/10.3389/tphar.2018.00299.

25. Gilca M., Gaman L., Panait E., Stoian I., Atanasiu V. (2010). Chelidonium majus - an integrative review: Traditional knowledge versus modern findings. Forschende Komplementarmedizin, 17(5), 241 248. https://doi.org/10.1159/000321397.

26. Matos O.C., Baeta J., Silva M.J., Pinto Ricardo C. Sensitivity of Fusarium strains to Chelidonium majus L. extracts. Journal of Ethnopharmacology. 1999. Vol. 66, No. 2. P. 151-158. https://doi.org/10.1016/S0378-8741(98)00183-4.

27. Parvu M., Parvu A.E., Craciun C., Barbu-Tudoran L., Tama§ M. Antifungal Activities of Chelidonium majus Extract on Botrytis cinerea in vitro and Ultrastructural Changes in its Conidia. Journal of Phytopathology. 2008. Vol. 156. P. 550-552. https://doi.org/10.1111/i.1439-0434.2008.01410.x.

28.